Gloeckner Sara Friederike, Meyne Felix, Wagner Fabian, Heinemann Uta, Krasnianski Anna, Meissner Bettina, Zerr Inga
Department of Neurology, Georg-August-University, Göttingen, Germany.
J Alzheimers Dis. 2008 May;14(1):17-25. doi: 10.3233/jad-2008-14102.
We carried out a quantitative analysis of transthyretin (TTR), total tau protein and amyloid-beta (Abeta) peptide (1-40 and 1-42) in the lumbar cerebrospinal fluid of 106 patients with different forms of dementia including Alzheimer's disease (AD), Creutzfeldt-Jakob-disease (CJD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) and normal pressure hydrocephalus (NPH) in comparison to healthy controls. Our study revealed that Abeta_{1-42} levels were decreased in all patients irrespective of dementia type. Tau protein levels were abnormal in all degenerative dementia except of NPH. Tau levels did not allow differential diagnosis of dementia type except for CJD, where we observed extremely high CSF levels. In other dementia types, levels were elevated in a similar range. Transthyretin levels were selectively decreased in AD and NPH, thus revealing the potential of this protein to be used as additional biomarker in the neurochemical differential diagnosis of AD. A significant negative correlation of TTR CSF levels and disease severity in AD was observed.
我们对106例患有不同形式痴呆症的患者（包括阿尔茨海默病（AD）、克雅氏病（CJD）、路易体痴呆（DLB）、额颞叶痴呆（FTD）和正常压力脑积水（NPH））的腰椎脑脊液中的转甲状腺素蛋白（TTR）、总tau蛋白和淀粉样β蛋白（Aβ）肽（1-40和1-42）进行了定量分析，并与健康对照者进行比较。我们的研究表明，无论痴呆类型如何，所有患者的Aβ1-42水平均降低。除NPH外，所有退行性痴呆患者的tau蛋白水平均异常。除CJD外，tau水平无法用于痴呆类型的鉴别诊断，在CJD患者中我们观察到脑脊液水平极高。在其他痴呆类型中，水平升高幅度相似。AD和NPH患者的转甲状腺素蛋白水平选择性降低，从而揭示了该蛋白在AD神经化学鉴别诊断中作为额外生物标志物的潜力。观察到AD患者脑脊液中TTR水平与疾病严重程度呈显著负相关。
